Press Release : 05-06-08
Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases. > More Info

Press Release : 04-25-08
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen. > More Info

Press Release: 04-18-08
Isis Reports Reduction of ApoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis. > More Info